Since increased expressions and high gene mutations of KRAS/MMP7/CD44 were found to promote CRC progression, metastasis, and resistance to current chemotherapies and targeted therapies, we further explored a computational approach to drug repurposing of sulfasalazine, a niclosamide derivative anti-inflammatory drug, which was recently shown to possess anticancer properties against human tumors [36,37]. The gene discussed is CD44; the disease is colorectal carcinoma.